Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dulanermin + rituximab
- Development stage
- Discontinued
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Dulanermin + rituximab is a combination investigational therapy composed of dulanermin—a recombinant form of the human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL; also known as Apo2L)—and rituximab, a monoclonal antibody targeting CD20 on B cells. Dulanermin induces apoptosis in cancer cells by binding to pro-apoptotic death receptors DR4 and DR5 (extrinsic apoptotic pathway), while rituximab promotes cell death via immune-mediated mechanisms. This combination was investigated in patients with relapsed or refractory low-grade (indolent) B-cell non-Hodgkin lymphoma, including follicular lymphoma, based on preclinical synergy between the agents. However, in clinical studies, the addition of dulanermin to rituximab did not improve objective response rate and development was terminated for lymphoma indications[1][2][3][4].
- Other names
- Apo2L/TRAIL + rituximab
02
Targets
Beyond the preview
Go deeper on dulanermin + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dulanermin + rituximab.